biotech · Lupus Nephritis · Primary or Secondary Progressive Multiple Sclerosis · KYTX
Kyverna Therapeutics
Kyverna Therapeutics is a biotech organization headquartered in Emeryville, USA. It trades on NYSE under ticker KYTX. Primary therapeutic focus areas include Lupus Nephritis, Primary or Secondary Progressive Multiple Scl
5980 Horton St, Suite 550, Emeryville, California 94608, US HQ
2018 Founded
155 Employees
Public company Type
KYTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 5980 Horton St, Suite 550, Emeryville, California 94608, US
- Founded
- 2018
- Employees
- 155
- Programs
- 14
- Drugs
- 31
- Patents
- 2
KYV-101
Phase 3 · small molecule · Lupus Nephritis, Systemic Sclerosis, Myasthenia Gravis, Rheumatoid Arthritis, Stiff Person Syndrome
KYV-101 for Lupus Nephritis, Systemic Sclerosis, Myasthenia Gravis, Rheumatoid Arthritis, Stiff Person Syndrome is a Phase 3 program (small_molecule) at Kyverna Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code KYV101-004
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Kyverna Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Lupus Nephritis, Systemic Sclerosis, Myasthenia Gravis, Rheumatoid Arthritis, Stiff Person Syndrome
- Status
- active
- Trials
- 1